{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T02:17:16Z","timestamp":1767147436237,"version":"build-2238731810"},"reference-count":15,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["jaci-inpractice.org","clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.jaip.2022.06.027","type":"journal-article","created":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T05:13:29Z","timestamp":1662527609000},"page":"2375-2377","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Mepolizumab in Hypereosinophilic Syndromes: Proposed Therapeutic Algorithm"],"prefix":"10.1016","volume":"10","author":[{"given":"Peter","family":"Valent","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2022.06.027_bib1","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/j.jaci.2007.02.010","article-title":"Eosinophilic disorders","volume":"119","author":"Simon","year":"2007","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.06.027_bib2","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jaci.2012.02.019","article-title":"Contemporary consensus on criteria and classification of eosinophil disorders and related syndromes","volume":"130","author":"Valent","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.06.027_bib3","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1146\/annurev-pathmechdis-012419-032756","article-title":"Contributions of eosinophils to human health and disease","volume":"15","author":"Klion","year":"2020","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.jaip.2022.06.027_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2021.100809","article-title":"Hypereosinophilic syndromes - An enigmatic group of disorders with an intriguing clinical spectrum and challenging treatment","volume":"49","author":"Helbig","year":"2021","journal-title":"Blood Rev"},{"key":"10.1016\/j.jaip.2022.06.027_bib5","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/j.jaip.2022.02.007","article-title":"Diagnosis and management of pediatric hypereosinophilic syndrome","volume":"10","author":"Rosenberg","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2022.06.027_bib6","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1056\/NEJMoa031261","article-title":"Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis","volume":"349","author":"Pl\u00f6tz","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2022.06.027_bib7","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jaci.2003.10.049","article-title":"Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes","volume":"113","author":"Garrett","year":"2004","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.06.027_bib8","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa070812","article-title":"Treatment of patients with the hypereosinophilic syndrome with mepolizumab","volume":"358","author":"Rothenberg","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2022.06.027_bib9","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1146\/annurev-pharmtox-010814-124407","article-title":"Novel targeted therapies for eosinophil-associated diseases and allergy","volume":"55","author":"Radonjic-Hoesli","year":"2015","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.jaip.2022.06.027_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1753466618808490","article-title":"Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience","volume":"12","author":"Emma","year":"2018","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.jaip.2022.06.027_bib11","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.jaci.2020.08.037","article-title":"Efficacy and safety of mepolizumab in hypereosinophilic syndrome: a phase III, randomized, placebo-controlled trial","volume":"146","author":"Roufosse","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.06.027_bib12","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1016\/j.jaip.2021.07.050","article-title":"Safety and efficacy of mepolizumab in hypereosinophilic syndrome: an open-label extension study","volume":"9","author":"Gleich","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2022.06.027_bib13","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1016\/j.jaip.2022.04.037","article-title":"Mepolizumab reduces hypereosinophilic syndrome flares irrespective of blood eosinophil count and interleukin-5","volume":"10","author":"Rothenberg","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2022.06.027_bib14","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S2213-2600(16)30031-5","article-title":"Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies","volume":"4","author":"Ortega","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2022.06.027_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2019.105806","article-title":"Baseline blood eosinophil count as a predictor of treatment response to the licensed dose of mepolizumab in severe eosinophilic asthma","volume":"159","author":"Albers","year":"2019","journal-title":"Respir Med"}],"updated-by":[{"DOI":"10.1016\/j.jaip.2022.09.014","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000}}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219822006493?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219822006493?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T09:52:31Z","timestamp":1664185951000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219822006493"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":15,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S2213219822006493"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2022.06.027","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mepolizumab in Hypereosinophilic Syndromes: Proposed Therapeutic Algorithm","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2022.06.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2022.04.037","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}